Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing
Sarah E. Ferguson(University Health Network), Blaise Clarke(Princess Margaret Cancer Centre), Steven Gallinger(Ontario Institute for Cancer Research), Jordan Lerner‐Ellis(Ontario Institute for Cancer Research), Helen Mackay(Sunnybrook Health Science Centre), Alicia Tone(BC Cancer Agency), Lua Eiriksson(Juravinski Hospital), Aaron Pollett(Mount Sinai Hospital), Zahra Alvandi(Boston Children's Hospital), Amit M. Oza(Ontario Institute for Cancer Research), Melyssa Aronson, Golnessa Mojtahedi(University Health Network), Christine Massey(University of Vermont), Marcus Q. Bernardini(University Health Network)
Cited by 141
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k